keyword
MENU ▼
Read by QxMD icon Read
search

esophageal cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/28816138/lymphocyte-nadir-and-esophageal-cancer-survival-outcomes-after-chemoradiation-therapy
#1
Rajayogesh Davuluri, Wen Jiang, Penny Fang, Cai Xu, Ritsuko Komaki, Daniel R Gomez, James Welsh, James D Cox, Christopher H Crane, Charles C Hsu, Steven H Lin
PURPOSE: Host immunity may affect the outcome in patients with esophageal cancer. We sought to identify factors that influenced absolute lymphocyte count (ALC) nadir during chemoradiation therapy (CRT) for esophageal cancer (EC) and looked for clinically relevant associations with survival. METHODS AND MATERIALS: 504 patients with stage I-III EC (2007-2013) treated with neoadjuvant or definitive CRT with weekly ALC determinations made during treatment were analyzed...
September 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28815073/predictive-factors-in-the-evaluation-of-treatment-response-to-neoadjuvant-chemoradiotherapy-in-patients-with-advanced-esophageal-squamous-cell-cancer
#2
REVIEW
Claudia Wong, Simon Law
Neoadjuvant therapy before esophagectomy is evidence-based, and is a standard-of-care for locally advanced and operable esophageal cancer. However response to such treatment varies in individual patients, from no clinical response to pathological complete response. It has been consistently shown that a good pathological responses is of prognostic value, but perhaps in the expense of those who do not. It is important to identify suitable predictive factors for response, so that patients are not exposed to potentially harmful chemotherapy and/or radiotherapy without benefits...
July 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28815065/neoadjuvant-treatment-of-locally-advanced-esophageal-and-junctional-cancer-the-evidence-base-current-key-questions-and-clinical-trials
#3
REVIEW
Claire L Donohoe, John V Reynolds
Recent trials, including CROSS, MAGIC, ACCORD, and OEO2, have established neoadjuvant therapy as standard of care for locally advanced (cT2-3NanyM0) esophageal and junctional cancer compared with surgery alone. The CROSS trial in particular defines a new benchmark for outcomes from multimodal therapy, with a 5 year survival rate of 47%, a median survival of 47 months, a pathologic complete response rate (pCR) of 29% and an R0 resection rate of 92%. Several key questions remain, in particular whether CROSS-regimen chemoradiotherapy is superior to neoadjuvant chemotherapy alone for esophageal cancer, in particular adenocarcinoma...
July 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28811720/endoscopic-occlusion-with-silicone-spigots-for-the-closure-of-refractory-esophago-bronchiole-fistula-after-esophagectomy
#4
Masaya Uesato, Tsuguaki Kono, Yasunori Akutsu, Kentarou Murakami, Akiko Kagaya, Yorihiko Muto, Akira Nakano, Mizuho Aikawa, Tomohide Tamachi, Hiroyuki Amagai, Takahiro Arasawa, Yasuhide Muto, Hisahiro Matsubara
A 65-year-old man with cT1bN0M0 stage I middle thoracic esophageal cancer underwent subtotal esophagectomy and gastric tube reconstruction through the posterior mediastinal route after preoperative carbon-ion radiotherapy and chemotherapy in a clinical trial. Anastomotic leakage occurred, but it spontaneously improved. At six months after the operation, he was rehospitalized with a cough and dysphagia. An esophago-bronchiole fistula and stenosis of the gastric tube were observed. He first underwent stent placement in the gastric tube...
July 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28807249/current-trends-in-multimodality-treatment-of-esophageal-and-gastroesophageal-junction-cancer-review-article
#5
REVIEW
Fredrik Klevebro, Simon Ekman, Magnus Nilsson
PURPOSE: Multimodality treatment has now been widely introduced in the curatively intended treatment of esophageal and gastroesophageal junction cancer. We aim to give an overview of the scientific evidence for the available treatment strategies and to describe which trends that are currently developing. METHODS: We conducted a review of the scientific evidence for the different curatively intended treatment strategies that are available today. Relevant articles of randomized controlled trials, cohort studies, and meta analyses were included...
September 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28807215/long-term-survival-based-on-pathologic-response-to-neoadjuvant-therapy-in-esophageal-cancer
#6
Gregory Tiesi, Wungki Park, Meredith Gunder, Gustavo Rubio, Michael Berger, Bach Ardalan, Alan Livingstone, Dido Franceschi
BACKGROUND: Neoadjuvant treatment is standard for locally advanced esophageal cancer. However, whether the addition of radiation to neoadjuvant regimen improves survival remains unclear. The aim of this study was to compare survival in locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus chemoradiation. MATERIALS AND METHODS: A prospectively maintained database of esophagectomies (1999-2012) was analyzed. We identified 297 patients with locally advanced esophageal cancer that underwent either neoadjuvant chemotherapy (n = 231) or chemoradiation (n = 66) followed by esophagectomy...
August 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28795280/the-use-of-neoadjuvant-therapy-for-resectable-locally-advanced-thoracic-esophageal-squamous-cell-carcinoma-in-an-analysis-of-5016-patients-from-305-designated-cancer-care-hospitals-in-japan
#7
Yoichiro Tsukada, Takahiro Higashi, Hideaki Shimada, Yoshinori Kikuchi, Atsuro Terahara
BACKGROUND: Recent studies have shown the benefits of neoadjuvant therapy with chemotherapy or chemoradiotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC). The aim of our study was to elucidate the use of neoadjuvant therapy for thoracic ESCC in Japan. METHODS: Data on patients with stage IB-III thoracic ESCC were retrieved from the national database of hospital-based cancer registries combined with claims data between 2012 and 2013...
August 9, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28777781/total-oxidant-antioxidant-status-in-sera-of-patients-with-esophageal-cancer
#8
Qingmei Huang, Jiafu Feng, Rong Wu, Yuwei Yang, Chunmei Dai, Jie Li, Yao Liao, Miao Xiang, Dong Wang, Xiao-Bo Du
BACKGROUND Oxidative stress parameters such as total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI) have been studied in breast, thyroid, and simple esophageal cancers (EC). We evaluated these parameters in patients with EC and analyzed their correlations with treatment outcomes. MATERIAL AND METHODS Serum TOS, TAS, and OSI in 92 patients with EC at different clinical stages and in 64 healthy people (controls) were measured. RESULTS Serum TOS, TAS, and OSI were significantly different between patients with EC and healthy controls (all p<0...
August 4, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28770168/neoadjuvant-therapy-for-esophageal-adenocarcinoma-in-the-community-setting-practice-and-outcomes
#9
Joe Abdo, Carrie A Bertellotti, David L Cornell, Devendra K Agrawal, Sumeet K Mittal
There has been an alarming rise in the incidence of esophageal adenocarcinoma which continues to have poor survival rates primarily due to lack of effective chemotherapy and presentation at advanced stages. Over a dozen chemotherapeutic agents are FDA approved for esophageal cancer (EC), and a two or three-drug combination is typically prescribed as first-line therapy for the majority of EC patients, administered either pre or post-operatively with esophageal resection. We have noticed significant variability in adjuvant and neoadjuvant regimens used in the community setting...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28760781/mir-432-induces-nrf2-stabilization-by-directly-targeting-keap1
#10
Burak Akdemir, Yasuaki Nakajima, Johji Inazawa, Jun Inoue
NF-E2-related factor 2 (NRF2) is a master transcriptional regulator that integrates cellular stress responses and is negatively regulated by Kelch-like ECH-associated protein 1 (KEAP1) at the post-translational level. In human cancers, aberrantly stabilized NRF2, by the mutation of either NRF2 or KEAP1 or by the potential inhibition of autophagy, plays a vital role in tumor growth and chemoresistance through the activation of target genes. MicroRNAs (miRNAs) are endogenous small noncoding RNAs that can negatively regulate gene expression by interfering with translation and/or stability of target transcripts...
July 31, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28755160/successful-video-assisted-thoracoscopic-surgery-in-prone-position-in-patients-with-esophageal-cancer-and-aberrant-right-subclavian-artery-report-of-three-cases
#11
Koji Shindo, Eishi Nagai, Toshinaga Nabae, Toru Eguchi, Taiki Moriyama, Kenoki Ohuchida, Tatsuya Manabe, Takao Ohtsuka, Yoshinao Oda, Makoto Hashizume, Masafumi Nakamura
BACKGROUND: An aberrant right subclavian artery (ARSA) with an associated nonrecurrent right inferior laryngeal nerve (NRILN) is a relatively rare anomaly that occurs at a frequency of 0.3 to 2.0% of the general population. NRILN has been mainly documented in the head and neck region; it has been rarely described in patients with esophageal cancer, especially those undergoing thoracoscopic surgery. Video-assisted thoracoscopic surgery for esophageal cancer (VATS-E) is becoming more widespread as a reliable minimally invasive surgical procedure associated with reduced perioperative complications...
December 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/28749231/phase-%C3%A2-study-of-concurrent-chemoradiotherapy-with-a-modified-target-volumes-delineation-method-for-inoperable-esophageal-cancer-patients
#12
Wenyi Zhang, Huifang Li, Xingxing Chen, Meng Su, Ruifang Lin, Changlin Zou
OBJECTIVE: A Phase || study was designed to test the safety and efficacy of concurrent chemoradiotherapy with a modified target volumes delineation method for inoperable esophageal cancer patients. METHODS: All eligible patients were treated with concurrent chemoradiotherapy. The method of delineating target volume was as follow: Planning gross target volume (PGTV) was defined as the primary gross tumor volume (GTV-t) plus a 3 cm margin longitudinally and a 0...
July 27, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28747249/surrogacy-of-progression-free-survival-pfs-for-overall-survival-os-in-esophageal-cancer-trials-with-preoperative-therapy-literature-based-meta-analysis
#13
K Kataoka, K Nakamura, J Mizusawa, K Kato, J Eba, H Katayama, T Shibata, H Fukuda
BACKGROUND: There have been no reports evaluating progression-free survival (PFS) as a surrogate endpoint in resectable esophageal cancer. This study was conducted to evaluate the trial level correlations between PFS and overall survival (OS) in resectable esophageal cancer with preoperative therapy and to explore the potential benefit of PFS as a surrogate endpoint for OS. METHODS: A systematic literature search of randomized trials with preoperative chemotherapy or preoperative chemoradiotherapy for esophageal cancer reported from January 1990 to September 2014 was conducted using PubMed and the Cochrane Library...
July 15, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28744724/concordance-of-clinical-diagnosis-of-t-classification-among-physicians-for-locally-advanced-unresectable-thoracic-esophageal-cancer
#14
Tomoya Yokota, Takushi Yasuda, Hiroyuki Kato, Isao Nozaki, Hiroshi Sato, Yoshinori Miyata, Yoshifumi Kuroki, Ken Kato, Yasuo Hamamoto, Yasuhiro Tsubosa, Hirofumi Ogawa, Yoshinori Ito, Yuko Kitagawa
BACKGROUND: We conducted a multicenter phase II trial assessing chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced, unresectable esophageal cancer. The aim of this study was to validate the concordance of clinical T diagnosis among physicians in the cases of this trial. METHODS: Computed tomography scans and esophagoscopic images of 48 patients taken at baseline were centrally reviewed by 6 senior physicians with experience in esophageal oncology...
July 25, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28742698/survival-benefit-of-neoadjuvant-treatment-in-clinical-t3n0m0-esophageal-cancer-results-from-a-retrospective-multicenter-european-study
#15
Styliani Mantziari, Caroline Gronnier, Florence Renaud, Alain Duhamel, Jérémie Théreaux, Cécile Brigand, Nicolas Carrère, Jérémie H Lefevre, Arnaud Pasquer, Nicolas Demartines, Denis Collet, Bernard Meunier, Christophe Mariette
BACKGROUND: Based on current guidelines, clinical T3N0M0 esophageal tumors may or may not receive neoadjuvant treatment, according to their perception as locally advanced (cT3) or early-stage tumors (stage II). The study aim was to assess the impact of neoadjuvant treatment upon survival for cT3N0M0 esophageal cancer patients, with subgroup analyses by histological type (squamous cell carcinoma vs adenocarcinoma) and type of neoadjuvant treatment (chemotherapy vs radiochemotherapy). METHODS: Data from patients operated on for esophageal cancer in 30 European centers were collected...
July 24, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28742685/recurrence-patterns-and-long-term-results-after-induction-chemotherapy-chemoradiotherapy-and-curative-surgery-in-patients-with-locally-advanced-esophageal-cancer
#16
Thomas Steffen, Daniel Dietrich, Annelies Schnider, Christoph Kettelhack, Olivier Huber, Walter R Marti, Markus Furrer, Beat Gloor, Marc Schiesser, Sandra Thierstein, Peter Brauchli, Thomas Ruhstaller
OBJECTIVE: The long-term follow up data of 2 prospective phase II trials is reported (NCT00072033, NCT00445861), which investigated neoadjuvant chemoradiation followed by surgery in patients with esophageal carcinoma. Postoperative complications as well as prognostic factors and patterns of relapse during long-term observation are shown. SUMMARY OF BACKGROUND DATA: Long-term follow-up is often missing in the complex setting of multimodal treatments of esophageal carcinoma; this leads to rather undifferentiated follow-up guidelines for this tumor entity...
July 24, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28741246/successful-resection-after-neoadjuvant-chemotherapy-for-esophageal-cancer-with-posterior-thoracic-paraaortic-lymph-node-metastasis-a-case-report-and-literature-review
#17
Yuji Shishido, Hiroshi Miyata, Keijirou Sugimura, Masaaki Motoori, Norikatsu Miyoshi, Masayoshi Yasui, Takeshi Omori, Masayuki Ohue, Yoshiyuki Fujiwara, Masahiko Yano
Metastasis to the posterior thoracic paraaortic lymph nodes rarely occurs in esophageal cancer, and a treatment strategy has not been established. We treated two cases of esophageal cancer with this type of metastasis; in both cases, we successfully performed surgical resection after neoadjuvant chemotherapy. In case 1, the patient received neoadjuvant chemotherapy, which consisted of docetaxel, cisplatin and 5-fluorouracil, and then underwent dissection of the posterior thoracic paraaortic lymph nodes. The left thoracic approach was used together with subtotal esophagectomy via a right thoracotomy...
July 24, 2017: General Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28739765/relationship-of-th17-treg-cells-and-radiation-pneumonia-in-locally-advanced-esophageal-carcinoma
#18
Yan Wang, Gang Xu, Jie Wang, Xin-Hua Li, Ping Sun, Wei Zhang, Jun-Xia Li, Chao-Yang Wu
BACKGROUND/AIM: Radiation pneumonia is a main side-effect that has limited the clinical usage of radiotherapy in locally advanced esophageal carcinoma. T helper cells 17 (Th 17) and T regulatory cells (Tregs) play an important role in inflammatory diseases. The balance between Treg and Th17 cells is a key factor in the progression of many inflammatory and autoimmune diseases. Whether Tregs and Th17 cells are predictive factors of radiation pneumonia has not yet been reported. In this study, we investigated the relationships of Treg/Th17 cells and radiation pneumonia in patients with locally advanced esophageal cancer who received radiotherapy...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28736635/immunotherapy-in-gastrointestinal-cancers
#19
REVIEW
Patrick Grierson, Kian-Huat Lim, Manik Amin
Gastrointestinal (GI) cancers such as gastric, esophageal, pancreas, hepatobiliary, colorectal and anal cancers are a major cause of cancer related mortality worldwide. Traditional treatment options such as chemotherapy, surgery, radiation therapy, monoclonal antibodies and anti-angiogenic agents have been the backbone of treatment of GI cancers in various stages. Current cancer research is moving forward to incorporate immunotherapies in the treatment of GI cancers either as single agent or in combination with current available treatment modalities...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28734226/inhibition-of-prb-pathway-differentially-modulates-apoptosis-in-esophageal-cancer-cells
#20
Rossana C Soletti, Deborah Biasoli, Nathassya A L V Rodrigues, João M A Delou, Renata Maciel, Vera L A Chagas, Rodrigo A P Martins, Stevens K Rehen, Helena L Borges
Esophageal cancer is the sixth most common cause of cancer-related death worldwide. Current chemotherapy regimens include a combination of 5-fluorouracil (5-FU) and cisplatin, but more efficient therapy strategies are needed to increase 5-year survival. Alterations in the signaling pathway of the tumor suppressor gene Rb-1, which encodes a phosphoprotein (pRB) that negatively regulates the G1/S transition of the cell cycle, are present in 70% of all tumors, but its role in esophageal cancer is still unclear...
July 19, 2017: Translational Oncology
keyword
keyword
40930
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"